Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167256 · ClinicalTrials.gov registry record · Phase 2
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT02167256 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 159 participants.
The verdict
NCT02167256, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.
Interventions
- DRUG Placebo
- DRUG AZD0530 100mg daily
- DRUG AZD0530 125mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02167256
The ClinicalTrials.gov registry entry for NCT02167256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02167256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02167256 about?
NCT02167256 is a clinical study titled "A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease". AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. More...
What is the current status of trial NCT02167256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2014-12. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02167256?
The interventions under investigation include: Placebo (DRUG), AZD0530 100mg daily (DRUG), AZD0530 125mg daily (DRUG).
Who is sponsoring clinical trial NCT02167256?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.